Clinical Trial

Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Trial Details
NCT Number NCT07650058
Lead Sponsor Ball State University
Collaborators: National Mango Board
Conditions Healthy Participants
Enrollment 35 participants
Start Date 2026-02-01
Primary Completion 2026-07 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-16